Tag: asundexian
Bayer granted priority review by US FDA for secondary stroke prevention...
Bayer has announced that the US Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) and granted priority review designation...
Asundexian found to reduce severity of secondary strokes
Bayer has announced late-breaking data from new analyses of the phase-three OCEANIC-STROKE study comparing asundexian versus placebo in combination with antiplatelet therapy. These analyses—presented...
Investigational Factor XIa inhibitor achieves reduction in secondary ischaemic stroke
The investigational anti-clotting medication asundexian (Bayer) has demonstrated a reduction in the risk of a second ischaemic stroke without raising bleeding-related concerns, according to preliminary...
